ClinicalTrials.gg
CompletedNCT02499770Updated Aug 21, 2020Results posted

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)

A Phase 1/2 interventional study of Carboplatin and Placebo in Small Cell Lung Cancer, sponsored by G1 Therapeutics, Inc.. Completed at 40 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-21.

Sponsored by G1 Therapeutics, Inc. (part of Pharmacosmos A/S) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 629 studies in Small Cell Lung Carcinoma with a site in United States — 111 open to participants now, 182 under way, 26 of them phase 3. Small Cell Lung Carcinoma · United States.

Enrollment
163rd of 550
122 · median 55
Started
2015
with 17 others
Phase 1/2
113 of 629
32 open now
Registered
297th of 629
by date

Among the 629 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 163rd largest by enrollment of the 550 interventional ones that give a count, is one of 18 that started in 2015, is one of 113 in phase 1/2, and was the 297th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

111 of the 629 studies in Small Cell Lung Carcinoma with a site in United States are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 629 studies in Small Cell Lung Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and etoposide in first line treatment for patients with newly diagnosed extensive-stage SCLC.

The study consists of 2 parts: a limited open-label, dose-finding portion (Part 1), and a randomized double-blind portion (Part 2). Both parts include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit. Approximately, 90 patients will be enrolled in the study; 20 patients in the Part 1 and 70 patients in the Part 2 portion.

03

Conditions studied

  • Small Cell Lung Cancer

Keywords

  • Small Cell Lung Cancer
  • CDK 4/6 Inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged ≥18 years
  • Unequivocally confirmed diagnosis of SCLC by histology or cytology, preferably including the presence of neuroendocrine features by immunohistochemistry
  • At least 1 target lesion that is unirradiated and measurable by , Version 1.1
  • (ECOG) performance status of 0 - 2
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Prior chemotherapy for extensive-stage SCLC
  • Presence of symptomatic requiring immediate treatment with radiation therapy or .
  • Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure
  • Known history of stroke or cerebrovascular accident within 6 months prior to enrollment
  • Other uncontrolled serious chronic disease or conditions that in the investigator's opinion could affect compliance or follow-up in the protocol
  • Concurrent radiotherapy to any site or radiotherapy within 2 weeks prior to enrollment or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response)
  • Receipt of any medication within 4 weeks prior to enrollment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    trilaciclib + carboplatin/etoposide

    All patients in part 1 will receive trilaciclib (G1T28) prior to standard chemotherapy- carboplatin and etoposide. Patients will have PK assessments completed on days 1 and 3 in cycle 1 only. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.

    Drug: Carboplatin · Drug: Trilaciclib · Drug: Etoposide

  • Experimental
    trilaciclib/placebo + carboplatin/etoposide

    All patients enrolled in part 2 will be randomized to receive either trilaciclib (G1T28) or placebo administered prior to standard chemotherapy- carboplatin and etoposide. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.

    Drug: Carboplatin · Drug: Placebo · Drug: Trilaciclib · Drug: Etoposide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities by Cohort in Cycle 1, Part 1

    Dose-limiting toxicities (DLTs) were drug-related toxicities defined as follows: 1. Absolute neutrophil count (ANC) \< 0.5 × 10\^9/L lasting for ≥ 7 days 2. ≥ Grade 3 neutropenic infection/febrile neutropenia 3. Grade 4 thrombocytopenia (TCP) or ≥ Grade 3 TCP with bleeding 4. Unable to start next cycle of chemotherapy due to lack of recovery to an ANC ≥ 1.5 × 10\^9/L and platelet count ≥ 100 × 10\^9/L 5. ≥ Grade 3 nonhematologic toxicity (nausea, vomiting, and diarrhea failing maximal medical management; fatigue lasting for \> 72 hours) Toxicities not clearly related to etoposide/carboplatin therapy were also considered for the purposes of determining DLTs.

    Time frame: Days 1-21 of Cycle 1

  2. Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Related AEs, Related SAEs, and AEs Leading to Study Drug Discontinuation in Part 1

    An AE was defined as any untoward medical occurrence in a participant administered a medicinal product that did not necessarily have a causal relationship with this treatment. TEAEs were defined as any AE that started on or after the first dose of study drug and up to the last dose +30 days. SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. Relatedness to study drug was assessed by the investigator. Related refers to those events that were Possibly, Probably, or Definitely Related. AEs with an unknown/not reported onset date were also included.

    Time frame: TEAEs were any AE that started on or after the first dose of study drug and up to the last dose +30 days (a minimum of 51 days up to a maximum of 374 days)

  3. Duration of Severe (Grade 4) Neutropenia in Part 2

    Severe (Grade 4) neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period. Within each cycle, the duration (days) of severe neutropenia was defined as the number of days from the date of the first ANC value of \<0.5 × 10\^9/L observed between start of cycle and end of cycle to the date of the first ANC value ≥0.5 × 10\^9/L that met the following criteria: 1) occurred after the ANC value of \<0.5 × 10\^9/L and 2) no other ANC values \<0.5 × 10\^9/L occurred between this day and end of cycle. The duration of severe neutropenia only included participants who had at least 1 severe neutropenia event in the cycle, and censoring rules were applied for unresolved severe neutropenia in a cycle. For the treatment period, the overall duration of severe neutropenia was the median value among the durations from all cycles.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Trilaciclib in Cycle 1, Part 1

    Cmax of trilaciclib in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used. For estimation of Cmax, a concentration that was below the limit of quantification (BLQ) was assigned a value of zero if it occurred in a profile before the first measurable concentration. If a BLQ value occurred after a measurable concentration in a profile, and was followed by a value above the lower limit of quantification, then the BLQ was treated as missing data. If a BLQ value occurred at the end of the collection interval (after the last quantifiable concentration) it was treated as missing data. If two BLQ values occurred in succession after Cmax, the profile was deemed to have terminated at the first BLQ value and any subsequent concentrations were omitted.

    Time frame: Days 1 and 3 of Cycle 1 for a 21-day cycle

  2. Area Under the Plasma Concentration Versus Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Trilaciclib in Cycle 1, Part 1

    AUC0-inf of trilaciclib in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.

    Time frame: Days 1 and 3 of Cycle 1 for a 21-day cycle

  3. Time of Maximum Observed Concentration (Tmax) of Trilaciclib in Cycle 1, Part 1

    Tmax of trilaciclib in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.

    Time frame: Days 1 and 3 of Cycle 1 for a 21-day cycle

  4. Cmax of Etoposide and Free and Total Carboplatin in Cycle 1, Part 1

    Cmax of etoposide and free and total carboplatin in plasma were determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used. For estimation of Cmax, a concentration that was BLQ was assigned a value of zero if it occurred in a profile before the first measurable concentration. If a BLQ value occurred after a measurable concentration in a profile, and was followed by a value above the lower limit of quantification, then the BLQ was treated as missing data. If a BLQ value occurred at the end of the collection interval (after the last quantifiable concentration) it was treated as missing data. If two BLQ values occurred in succession after Cmax, the profile was deemed to have terminated at the first BLQ value and any subsequent concentrations were omitted.

    Time frame: Days 1 and 3 of Cycle 1 for a 21-day cycle (carboplatin was only dosed on Day 1 so there are no Day 3 Cmax values)

  5. AUC0-inf of Etoposide and Free and Total Carboplatin in Cycle 1, Part 1

    AUC0-inf of etoposide and free and total carboplatin in plasma were determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.

    Time frame: Days 1 and 3 of Cycle 1 for a 21-day cycle (carboplatin was only dosed on Day 1 so there are no Day 3 AUC0-inf values)

  6. Tmax of Etoposide and Free and Total Carboplatin in Cycle 1, Part 1

    Tmax of etoposide and free and total carboplatin in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.

    Time frame: Days 1 and 3 of Cycle 1 for a 21-day cycle (carboplatin was only dosed on Day 1 so there are no Day 3 Tmax values)

  7. Duration of Severe (Grade 4) Neutropenia in Part 1

    Severe (Grade 4) neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period. Within each cycle, the duration (days) of severe neutropenia was defined as the number of days from the date of the first ANC value of \<0.5 × 10\^9/L observed between start of cycle and end of cycle to the date of the first ANC value ≥0.5 × 10\^9/L that met the following criteria: 1) occurred after the ANC value of \<0.5 × 10\^9/L and 2) no other ANC values \<0.5 × 10\^9/L occurred between this day and end of cycle. The duration of severe neutropenia only included participants who had at least 1 severe neutropenia event in the cycle, and censoring rules were applied for unresolved severe neutropenia in a cycle. For the treatment period, the overall duration of severe neutropenia was the median value among the durations from all cycles.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  8. Occurrence of Severe (Grade 4) Neutropenia in Part 1

    Severe (Grade 4) neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  9. Occurrence of Febrile Neutropenia in Part 1

    Each febrile neutropenia event (as defined by Common Terminology Criteria for Adverse Events \[CTCAE\]) was captured as an AE. The occurrence of febrile neutropenia was defined as at least 1 febrile neutropenia event during the treatment period. For the treatment period, the total number of febrile neutropenia events was the number of febrile neutropenia events with a unique start date.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  10. Duration of Grade 3/4 Neutropenia in Part 1

    Grade 3/4 neutropenia was defined as at least 1 ANC value \<1.0 × 10\^9/L during the treatment period. Within each cycle, duration (days) of Grade 3/4 neutropenia was defined as the number of days from the date of the first ANC value of \<1.0 × 10\^9/L observed between start of cycle and end of cycle to the date of the first ANC value ≥1.0 × 10\^9/L that met the following criteria: 1) occurred after the ANC value of \<1.0 × 10\^9/L and 2) no other ANC values \<1.0 × 10\^9/L occurred between this day and end of cycle. The duration of Grade 3/4 neutropenia only included participants who had at least 1 Grade 3/4 neutropenia event in the cycle, and censoring rules were applied for unresolved Grade 3/4 neutropenia in a cycle. For the treatment period, the overall duration of Grade 3/4 neutropenia was the median value among the durations of Grade 3/4 neutropenia from all cycles.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  11. Occurrence of Grade 3/4 Neutropenia in Part 1

    Grade 3/4 neutropenia was defined as at least 1 ANC value \<1.0 × 10\^9/L during the treatment period.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  12. Nadir of Absolute Neutrophil Count in Cycle 1, Part 1

    Cycle nadir was the lowest value for ANC that occurred between start of cycle and end of cycle and was less than the cycle baseline.

    Time frame: From baseline to the end of Cycle 1

  13. Occurrence of Granulocyte-Colony Stimulating Factor (G-CSF) Administration in Part 1

    Administration of G-CSF was collected with concomitant medications, which were coded using World Health Organization Drug Dictionary (WHO-DD) Version September 2017. A cycle where G-CSF was administered concurrently was identified by comparing the start and stop dates of each administration of G-CSF to the start of cycle and end of cycle. The occurrence of G-CSF administrations was defined as at least 1 cycle with G-CSF administrations during the treatment period. For the treatment period, the total number of G-CSF administrations was the number of cycles with G-CSF administrations.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  14. Occurrence of Red Blood Cell (RBC) Transfusion in Part 1

    Within a cycle, a RBC transfusion event was defined as either 1) an actual RBC transfusion, or 2) eligible for RBC transfusion (defined as hemoglobin \<8.0 g/dL). The occurrence of RBC transfusions was defined as at least 1 cycle with RBC transfusion during the treatment period. For the treatment period, the total number of RBC transfusions was the number of cycles with RBC transfusions.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  15. Change From Baseline of Hemoglobin at the End of Cycle 6, Part 1

    Blood samples were collected for local clinical laboratory assessment of hemoglobin levels.

    Time frame: Baseline, Day 1, Day 3, Day 8, Day 10, and Day 15 of a 21-day cycle x 6

  16. Occurrence of Erythropoietin Stimulating Agent (ESA) Administration in Part 1

    Administration of ESAs was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where an ESA was administered concurrently was identified by comparing the start and stop dates of each administration of an ESA to the start of cycle and end of cycle. The occurrence of ESA administration was at least 1 cycle with an ESA administration during the treatment period. For the treatment period, the total number of ESA administrations was the number of cycles with ESA administrations.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  17. Occurrence of Platelet Transfusion in Part 1

    Within a cycle, a platelet transfusion event was defined as either 1) an actual platelet transfusion, or 2) eligible for platelet transfusion (defined as a platelet count ≤10 × 10\^9/L). The occurrence of platelet transfusions was defined as at least 1 cycle with platelet transfusion during the treatment period. For the treatment period, the total number of platelet transfusions was the number of cycles with platelet transfusions.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  18. Change From Baseline of Platelet Count at the End of Cycle 6, Part 1

    Blood samples were collected for local clinical laboratory assessment of platelet count.

    Time frame: Baseline, Day 1, Day 3, Day 8, Day 10, and Day 15 of a 21-day cycle x 6

  19. Change From Baseline of Lymphocyte Count at the End of Cycle 6, Part 1

    Blood samples were collected for local clinical laboratory assessment of lymphocyte count.

    Time frame: Baseline, Day 1, Day 3, Day 8, Day 10, and Day 15 of a 21-day cycle x 6

  20. Occurrence of Dose Reduction in Part 1

    Dose reductions were not permitted for trilaciclib, per study protocol. Dose reductions for E/P were derived from changes in the protocol-specified dose on the dosing page and corresponded to the reductions for toxicity specified in the protocol. No more than 2 dose reductions of E/P in total were allowed for any participant. Simultaneous reductions in the doses of E/P were counted as 1 dose reduction. For the treatment period, the total number of dose reductions was the number of cycles where there was at least 1 dose reduction.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  21. Occurrence of Infectious SAEs in Part 1

    SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. An infectious SAE was a serious event in the Medical Dictionary for Regulatory Activities (MedDRA) system organ class "infections and infestations" and a preferred term of anal abscess, bacteraemia, bronchitis, candida infection, chronic sinusitis, conjunctivitis, infection, influenza, nasopharyngitis, oral candidiasis, oral herpes, pharyngitis streptococcal, pneumonia, pneumonia bacterial, respiratory tract infection, sepsis, skin infection, upper respiratory tract infection, urinary tract infection, urosepsis or viral upper respiratory tract infection.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  22. Occurrence of Pulmonary Infection SAE in Part 1

    SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. A pulmonary infection SAE was a serious event in the MedDRA system organ class "infections and infestations" and a preferred term of bronchitis, influenza, pneumonia, pneumonia bacterial, respiratory tract infection, upper respiratory tract infection or viral upper respiratory tract infection.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  23. Occurrence of IV Antibiotic Administration in Part 1

    Intravenous antibiotic administration was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where IV antibiotic was administered concurrently was identified by comparing the start and stop dates of each administration of IV antibiotic to the start of cycle and end of cycle. The occurrence of IV antibiotic administration was defined as at least 1 cycle with IV antibiotic administration during the treatment period. For the treatment period, the total number of IV antibiotic administrations was the number of cycles with IV antibiotic administrations.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  24. Time to First Major Adverse Hematologic Event (MAHE) in Part 1

    MAHE was a composite endpoint incorporating the measurement of several clinically meaningful aspects of myelopreservation into a single endpoint. The individual components for MAHE were hospitalization for a hematologic event, febrile neutropenia, death related to treatment, dose delay/reduction due to ANC or platelet counts, prolonged severe neutropenia (duration \>5 days), RBC transfusion (actual or eligible) and platelet transfusion (actual or eligible). Time to first occurrence of a MAHE event was defined as the first time to observe an interested event among all the components, starting from the first dose date of study drug administration.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  25. Best Overall Tumor Response Based on Assessments in Part 1

    Tumor response was assessed by computed tomography (CT) or magnetic resonance imaging (MRI). Overall visit response by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was derived programmatically using data from target lesions (TLs), non-target lesions (NTLs), \& new lesions. Tumor response data were used to determine each participant's time point response \& best overall response (BOR). Complete response (CR) was disappearance of all TLs, any pathological lymph nodes selected as TLs must have reduced in short axis to \<10 mm. Partial response (PR) was at least a 30% decrease from baseline in the sum of diameters of TLs, as long as criteria for progressive disease (PD) were not met. PD was a ≥20% increase in the smallest sum of diameters of TLs since treatment started (including baseline) and an absolute increase of ≥5 mm. Stable disease (SD) was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: Baseline, end of every two 21-day cycles, up until disease progression to a maximum of the time at least 70% overall survival (OS) events observed (a maximum of 4 years)

  26. Best Overall Tumor Response Based on Blinded Independent Central Review (BICR) Assessments in Part 1

    Tumor response was assessed by CT or MRI. Overall visit response by RECIST v1.1 was determined by BICR. Tumor response data were used to determine each participant's time point response \& BOR. CR was disappearance of all TLs, any pathological lymph nodes selected as TLs must have reduced in short axis to \<10 mm. PR was at least a 30% decrease from baseline in the sum of diameters of TLs, as long as criteria for PD were not met. PD was a ≥20% increase in the smallest sum of diameters of TLs since treatment started (including baseline) and an absolute increase of ≥5 mm. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: Baseline, end of every two 21-day cycles, up until disease progression to a maximum of the time at least 70% OS events observed (a maximum of 4 years)

  27. Progression Free Survival (PFS) Based on Assessments in Part 1

    Tumor response was assessed by CT or MRI. PFS was defined as the time (months) from date of first dose date of study drug for participants in Part 1 until date of documented disease progression or death due to any cause, whichever occurred first. More specifically, PFS was determined using all the assessment data up until the last evaluable visit prior to or on the date of i) disease progression as defined by RECIST 1.1 or by clinical criteria as determined by the investigator; or ii) withdrawal of consent; or iii) receiving subsequent anticancer therapy, whichever was earlier. For PFS determined using response data derived programmatically, either clinical progression or progression by RECIST (whichever came first) was considered. Median and inter-quartile range of PFS were calculated using the Kaplan-Meier method.

    Time frame: Baseline, end of every two 21-day cycles, up until disease progression to a maximum of the time at least 70% OS events observed (a maximum of 4 years)

  28. OS in Part 1

    OS was calculated as the time (months) from date of first dose of study drug for participants in Part 1 to the date of death due to any cause. Participants who did not die during the study were censored at the date last known to be alive. Participants lacking data beyond the day of first dose of study drug had their survival time censored at day of first dose of study drug. OS was not censored if a participant received other anti-tumor treatments after the study drugs. Median and inter-quartile range of OS were calculated using the Kaplan-Meier method.

    Time frame: Baseline up until death or a maximum of the time at least 70% OS events observed (a maximum of 4 years)

  29. Occurrence of Severe (Grade 4) Neutropenia in Part 2

    Severe (Grade 4) neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  30. Occurrence of Febrile Neutropenia in Part 2

    Each febrile neutropenia event (as defined by CTCAE) was captured as an AE. The occurrence of febrile neutropenia was defined as at least 1 febrile neutropenia event during the treatment period. For the treatment period, the total number of febrile neutropenia events was the number of febrile neutropenia events with a unique start date.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  31. Duration of Grade 3/4 Neutropenia in Part 2

    Grade 3/4 neutropenia was defined as at least 1 ANC value \<1.0 × 10\^9/L during the treatment period. Within each cycle, duration (days) of Grade 3/4 neutropenia was defined as the number of days from the date of the first ANC value of \<1.0 × 10\^9/L observed between start of cycle and end of cycle to the date of the first ANC value ≥1.0 × 10\^9/L that met the following criteria: 1) occurred after the ANC value of \<1.0 × 10\^9/L and 2) no other ANC values \<1.0 × 10\^9/L occurred between this day and end of cycle. The duration of Grade 3/4 neutropenia only included participants who had at least 1 Grade 3/4 neutropenia event in the cycle, and censoring rules were applied for unresolved Grade 3/4 neutropenia in a cycle. For the treatment period, the overall duration of Grade 3/4 neutropenia was the median value among the durations of Grade 3/4 neutropenia from all cycles.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  32. Occurrence of Grade 3/4 Neutropenia in Part 2

    Grade 3/4 neutropenia was defined as at least 1 ANC value \<1.0 × 10\^9/L during the treatment period.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  33. Nadir of Absolute Neutrophil Count in Cycle 1, Part 2

    Cycle nadir was the lowest value for ANC that occurred between start of cycle and end of cycle and was less than the cycle baseline.

    Time frame: From baseline to the end of Cycle 1

  34. Occurrence of G-CSF Administration in Part 2

    Administration of G-CSF was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where G-CSF was administered concurrently was identified bycomparing the start and stop dates of each administration of G-CSF to the start of cycle and end of cycle. The occurrence of G-CSF administrations was defined as at least 1 cycle with G-CSF administrations during the treatment period. For the treatment period, the total number of G-CSF administrations was the number of cycles with G-CSF administrations.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  35. Occurrence of RBC Transfusion in Part 2

    Within a cycle, a RBC transfusion event was defined as either 1) an actual RBC transfusion, or 2) eligible for RBC transfusion (defined as hemoglobin \<8.0 g/dL). The occurrence of RBC transfusions was defined as at least 1 cycle with RBC transfusion during the treatment period. For the treatment period, the total number of RBC transfusions was the number of cycles with RBC transfusions. If a participant did not have any RBC transfusions, they were assigned a value of 0.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  36. Change From Baseline of Hemoglobin at the End of Cycle 6, Part 2

    Blood samples were collected for local clinical laboratory assessment of hemoglobin levels.

    Time frame: Baseline, Day 1, Day 3, Day 8, Day 10, and Day 15 of a 21-day cycle x 6

  37. Occurrence of ESA Administration in Part 2

    Administration of ESAs was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where an ESA was administered concurrently was identified by comparing the start and stop dates of each administration of an ESA to the start of cycle and end of cycle. The occurrence of ESA administration was at least 1 cycle with an ESA administration during the treatment period. For the treatment period, the total number of ESA administrations was the number of cycles with ESA administrations.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  38. Occurrence of Platelet Transfusion in Part 2

    Within a cycle, a platelet transfusion event was defined as either 1) an actual platelet transfusion, or 2) eligible for platelet transfusion (defined as a platelet count ≤10 × 10\^9/L). The occurrence of platelet transfusions was defined as at least 1 cycle with platelet transfusion during the treatment period. For the treatment period, the total number of platelet transfusions was the number of cycles with platelet transfusions.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  39. Change From Baseline of Platelet Count at the End of Cycle 6, Part 2

    Blood samples were collected for local clinical laboratory assessment of platelet count.

    Time frame: Baseline, Day 1, Day 3, Day 8, Day 10, and Day 15 of a 21-day cycle x 6

  40. Change From Baseline of Lymphocyte Count at the End of Cycle 6, Part 2

    Blood samples were collected for local clinical laboratory assessment of lymphocyte count.

    Time frame: Baseline, Day 1, Day 3, Day 8, Day 10, and Day 15 of a 21-day cycle x 6

  41. Occurrence of Dose Reduction in Part 2

    Dose reductions were not permitted for trilaciclib, per study protocol. Dose reductions for E/P were derived from changes in the protocol-specified dose on the dosing page and corresponded to the reductions for toxicity specified in the protocol. No more than 2 dose reductions of E/P in total were allowed for any participant. Simultaneous reductions in the doses of E/P were counted as 1 dose reduction. For the treatment period, the total number of dose reductions was the number of cycles where there was at least 1 dose reduction.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  42. Occurrence of Infectious SAEs in Part 2

    SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. An infectious SAE was a serious event in the MedDRA system organ class "infections and infestations" and a preferred term of anal abscess, bacteraemia, bronchitis, candida infection, chronic sinusitis, conjunctivitis, infection, influenza, nasopharyngitis, oral candidiasis, oral herpes, pharyngitis streptococcal, pneumonia, pneumonia bacterial, respiratory tract infection, sepsis, skin infection, upper respiratory tract infection, urinary tract infection, urosepsis or viral upper respiratory tract infection.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  43. Occurrence of Pulmonary Infection SAE in Part 2

    SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. A pulmonary infection SAE was a serious event in the MedDRA system organ class "infections and infestations" and a preferred term of bronchitis, influenza, pneumonia, pneumonia bacterial, respiratory tract infection, upper respiratory tract infection or viral upper respiratory tract infection.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  44. Occurrence of IV Antibiotic Administration in Part 2

    Intravenous antibiotic administration was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where IV antibiotic was administered concurrently was identified by comparing the start and stop dates of each administration of IV antibiotic to the start of cycle and end of cycle. The occurrence of IV antibiotic administration was defined as at least 1 cycle with IV antibiotic administration during the treatment period. For the treatment period, the total number of IV antibiotic administrations was the number of cycles with IV antibiotic administrations.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  45. Time to First MAHE in Part 2

    MAHE was a composite endpoint incorporating the measurement of several clinically meaningful aspects of myelopreservation into a single endpoint. The individual components for MAHE were hospitalization for a hematologic event, febrile neutropenia, death related to treatment, dose delay/reduction due to ANC or platelet counts, prolonged severe neutropenia (duration \>5 days), RBC transfusion (actual or eligible) and platelet transfusion (actual or eligible). Time to first occurrence of a MAHE event was defined as the first time to observe an interested event among all the components, starting from the first dose date of study drug administration.

    Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)

  46. Best Overall Tumor Response Based on Assessments in Part 2

    Tumor response was assessed by CT or MRI. Overall visit response by RECIST v1.1 was derived programmatically using data from TLs, NTLs, \& new lesions. Tumor response data were used to determine each participant's time point response \& BOR. CR was disappearance of all TLs, any pathological lymph nodes selected as TLs must have reduced in short axis to \<10 mm. PR was at least a 30% decrease from baseline in the sum of diameters of TLs, as long as criteria for PD were not met. PD was a ≥20% increase in the smallest sum of diameters of TLs since treatment started (including baseline) and an absolute increase of ≥5 mm. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: Baseline, end of every two 21-day cycles, up until disease progression to a maximum of the time at least 70% OS events observed (a maximum of 4 years)

  47. Best Overall Tumor Response Based on BICR Assessments in Part 2

    Tumor response was assessed by CT or MRI. Overall visit response by RECIST v1.1 was determined by BICR. Tumor response data were used to determine each participant's time point response \& BOR. CR was disappearance of all TLs, any pathological lymph nodes selected as TLs must have reduced in short axis to \<10 mm. PR was at least a 30% decrease from baseline in the sum of diameters of TLs, as long as criteria for PD were not met. PD was a ≥20% increase in the smallest sum of diameters of TLs since treatment started (including baseline) and an absolute increase of ≥5 mm. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: Baseline, end of every two 21-day cycles, up until disease progression to a maximum of the time at least 70% OS events observed (a maximum of 4 years)

  48. PFS Based on Assessments in Part 2

    Tumor response was assessed by CT or MRI. PFS was defined as the time (months) from date of first dose date of study drug for participants in Part 1 until date of documented disease progression or death due to any cause, whichever occurred first. More specifically, PFS was determined using all the assessment data up until the last evaluable visit prior to or on the date of i) disease progression as defined by RECIST 1.1 or by clinical criteria as determined by the investigator; or ii) withdrawal of consent; or iii) receiving subsequent anticancer therapy, whichever was earlier. For PFS determined using response data derived programmatically, either clinical progression or progression by RECIST (whichever came first) was considered. Median and inter-quartile range of PFS were calculated using the Kaplan-Meier method.

    Time frame: Baseline, end of every two 21-day cycles, up until disease progression to a maximum of the time at least 70% OS events observed (a maximum of 4 years)

  49. OS in Part 2

    OS was calculated as the time (months) from date of first dose of study drug for participants in Part 2 to the date of death due to any cause. Participants who did not die during the study were censored at the date last known to be alive. Participants lacking data beyond the day of first dose of study drug had their survival time censored at day of first dose of study drug. OS was not censored if a participant received other anti-tumor treatments after the study drugs. Median and inter-quartile range of OS were calculated using the Kaplan-Meier method.

    Time frame: Baseline up until death or a maximum of the time at least 70% OS events observed (a maximum of 4 years)

07

Results

Posted Jul 9, 2020

Participant flow

The study was conducted at 71 centers in the United States of America and Europe. The first participant enrolled on 26 June 2015 and the last participant completed on 22 February 2019. For Part 1, participants were enrolled from 26 June 2015 to 30 September 2016 and for Part 2, participants were enrolled from 06 October 2016 to 25 April 2017.

Participant flow — Overall Study
MilestonePart 1: Dose Finding/ExpansionPart 2: Trilaciclib/Placebo IV With E/P
Started1977
Completed00
Not completed1977
Withdrew: Death1756
Withdrew: Study completion110
Withdrew: Withdrawal by subject07
Withdrew: Lost to follow-up02
Withdrew: Subject declined further treatment10
Withdrew: Withdrawn by pi for compassionate reason01
Withdrew: Randomized but not enrolled01

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities by Cohort in Cycle 1, Part 1

Dose-limiting toxicities (DLTs) were drug-related toxicities defined as follows: 1. Absolute neutrophil count (ANC) \< 0.5 × 10\^9/L lasting for ≥ 7 days 2. ≥ Grade 3 neutropenic infection/febrile neutropenia 3. Grade 4 thrombocytopenia (TCP) or ≥ Grade 3 TCP with bleeding 4. Unable to start next cycle of chemotherapy due to lack of recovery to an ANC ≥ 1.5 × 10\^9/L and platelet count ≥ 100 × 10\^9/L 5. ≥ Grade 3 nonhematologic toxicity (nausea, vomiting, and diarrhea failing maximal medical management; fatigue lasting for \> 72 hours) Toxicities not clearly related to etoposide/carboplatin therapy were also considered for the purposes of determining DLTs.

Time frame:
Days 1-21 of Cycle 1
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities by Cohort in Cycle 1, Part 1
ParticipantsPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Number of participants meeting ≥1 DLT criteria21
Grade 4 TCP or ≥Grade 3 TCP with bleeding10
Unable to start next cycle of chemotherapy11
PrimaryIncidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Related AEs, Related SAEs, and AEs Leading to Study Drug Discontinuation in Part 1

An AE was defined as any untoward medical occurrence in a participant administered a medicinal product that did not necessarily have a causal relationship with this treatment. TEAEs were defined as any AE that started on or after the first dose of study drug and up to the last dose +30 days. SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. Relatedness to study drug was assessed by the investigator. Related refers to those events that were Possibly, Probably, or Definitely Related. AEs with an unknown/not reported onset date were also included.

Time frame:
TEAEs were any AE that started on or after the first dose of study drug and up to the last dose +30 days (a minimum of 51 days up to a maximum of 374 days)
Reported as:
Count of participants · Participants
Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Related AEs, Related SAEs, and AEs Leading to Study Drug Discontinuation in Part 1
ParticipantsPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Any TEAE128
Any SAE41
TEAE related to any study drug108
SAE related to any study drug00
TEAE leading to discontinuation of any study drug00
PrimaryDuration of Severe (Grade 4) Neutropenia in Part 2

Severe (Grade 4) neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period. Within each cycle, the duration (days) of severe neutropenia was defined as the number of days from the date of the first ANC value of \<0.5 × 10\^9/L observed between start of cycle and end of cycle to the date of the first ANC value ≥0.5 × 10\^9/L that met the following criteria: 1) occurred after the ANC value of \<0.5 × 10\^9/L and 2) no other ANC values \<0.5 × 10\^9/L occurred between this day and end of cycle. The duration of severe neutropenia only included participants who had at least 1 severe neutropenia event in the cycle, and censoring rules were applied for unresolved severe neutropenia in a cycle. For the treatment period, the overall duration of severe neutropenia was the median value among the durations from all cycles.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Median · Days
Duration of Severe (Grade 4) Neutropenia in Part 2
DaysPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Duration of Severe (Grade 4) Neutropenia in Part 28 (7 to 8)3 (2 to 3)
Statistical analysis
  • Part 2: Placebo vs Part 2: Trilaciclib 240 mg/m^2 · Stratified log-rank test · p = = 0.0097 (The p-value was calculated using the stratified log-rank test to account for the baseline ECOG status (0-1 vs 2) as the stratification factor. Significance level was set as two-sided 0.2.)p-value calculated using stratified log-rank test with baseline ECOG status (0-1 vs 2) as stratification factor. Significance level was two-sided 0.2.
SecondaryMaximum Observed Plasma Concentration (Cmax) of Trilaciclib in Cycle 1, Part 1

Cmax of trilaciclib in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used. For estimation of Cmax, a concentration that was below the limit of quantification (BLQ) was assigned a value of zero if it occurred in a profile before the first measurable concentration. If a BLQ value occurred after a measurable concentration in a profile, and was followed by a value above the lower limit of quantification, then the BLQ was treated as missing data. If a BLQ value occurred at the end of the collection interval (after the last quantifiable concentration) it was treated as missing data. If two BLQ values occurred in succession after Cmax, the profile was deemed to have terminated at the first BLQ value and any subsequent concentrations were omitted.

Time frame:
Days 1 and 3 of Cycle 1 for a 21-day cycle
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Trilaciclib in Cycle 1, Part 1
ng/mLPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Day 1 Cycle 11240 ± 7381570 ± NA
Day 3 Cycle 11620 ± 10402260 ± NA
SecondaryArea Under the Plasma Concentration Versus Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Trilaciclib in Cycle 1, Part 1

AUC0-inf of trilaciclib in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.

Time frame:
Days 1 and 3 of Cycle 1 for a 21-day cycle
Reported as:
Mean · h*ng/mL
Area Under the Plasma Concentration Versus Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Trilaciclib in Cycle 1, Part 1
h*ng/mLPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Day 1 Cycle 12560 ± 7922280 ± NA
Day 3 Cycle 13110 ± 6932960 ± NA
SecondaryTime of Maximum Observed Concentration (Tmax) of Trilaciclib in Cycle 1, Part 1

Tmax of trilaciclib in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.

Time frame:
Days 1 and 3 of Cycle 1 for a 21-day cycle
Reported as:
Median · Hours
Time of Maximum Observed Concentration (Tmax) of Trilaciclib in Cycle 1, Part 1
HoursPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Day 1 Cycle 10.57 (0.45 to 0.98)0.50 (NA to NA)
Day 3 Cycle 10.52 (0.47 to 1.00)0.45 (NA to NA)
SecondaryCmax of Etoposide and Free and Total Carboplatin in Cycle 1, Part 1

Cmax of etoposide and free and total carboplatin in plasma were determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used. For estimation of Cmax, a concentration that was BLQ was assigned a value of zero if it occurred in a profile before the first measurable concentration. If a BLQ value occurred after a measurable concentration in a profile, and was followed by a value above the lower limit of quantification, then the BLQ was treated as missing data. If a BLQ value occurred at the end of the collection interval (after the last quantifiable concentration) it was treated as missing data. If two BLQ values occurred in succession after Cmax, the profile was deemed to have terminated at the first BLQ value and any subsequent concentrations were omitted.

Time frame:
Days 1 and 3 of Cycle 1 for a 21-day cycle (carboplatin was only dosed on Day 1 so there are no Day 3 Cmax values)
Reported as:
Mean · μg/mL
Cmax of Etoposide and Free and Total Carboplatin in Cycle 1, Part 1
μg/mLPart 1: Dose Finding/Expansion
Etoposide Day 1 Cycle 121.9 ± 2.70
Etoposide Day 3 Cycle 120.2 ± 2.40
Free Carboplatin Day 1 Cycle 120.3 ± 6.83
Total Carboplatin Day 1 Cycle 118.8 ± 5.45
SecondaryAUC0-inf of Etoposide and Free and Total Carboplatin in Cycle 1, Part 1

AUC0-inf of etoposide and free and total carboplatin in plasma were determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.

Time frame:
Days 1 and 3 of Cycle 1 for a 21-day cycle (carboplatin was only dosed on Day 1 so there are no Day 3 AUC0-inf values)
Reported as:
Mean · h*μg/mL
AUC0-inf of Etoposide and Free and Total Carboplatin in Cycle 1, Part 1
h*μg/mLPart 1: Dose Finding/Expansion
Etoposide Day 1 Cycle 1131 ± 44.7
Etoposide Day 3 Cycle 1146 ± 48.4
Free Carboplatin Day 1 Cycle 150.5 ± 14.4
Total Carboplatin Day 1 Cycle 1137 ± 37.3
SecondaryTmax of Etoposide and Free and Total Carboplatin in Cycle 1, Part 1

Tmax of etoposide and free and total carboplatin in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.

Time frame:
Days 1 and 3 of Cycle 1 for a 21-day cycle (carboplatin was only dosed on Day 1 so there are no Day 3 Tmax values)
Reported as:
Median · Hours
Tmax of Etoposide and Free and Total Carboplatin in Cycle 1, Part 1
HoursPart 1: Dose Finding/Expansion
Etoposide Day 1 Cycle 11.08 (0.90 to 2.67)
Etoposide Day 3 Cycle 11.00 (0.85 to 1.52)
Free Carboplatin Day 1 Cycle 10.52 (0.47 to 0.67)
Total Carboplatin Day 1 Cycle 10.52 (0.47 to 0.67)
SecondaryDuration of Severe (Grade 4) Neutropenia in Part 1

Severe (Grade 4) neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period. Within each cycle, the duration (days) of severe neutropenia was defined as the number of days from the date of the first ANC value of \<0.5 × 10\^9/L observed between start of cycle and end of cycle to the date of the first ANC value ≥0.5 × 10\^9/L that met the following criteria: 1) occurred after the ANC value of \<0.5 × 10\^9/L and 2) no other ANC values \<0.5 × 10\^9/L occurred between this day and end of cycle. The duration of severe neutropenia only included participants who had at least 1 severe neutropenia event in the cycle, and censoring rules were applied for unresolved severe neutropenia in a cycle. For the treatment period, the overall duration of severe neutropenia was the median value among the durations from all cycles.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Median · Days
Duration of Severe (Grade 4) Neutropenia in Part 1
DaysPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Duration of Severe (Grade 4) Neutropenia in Part 16 (6 to 7)—
SecondaryOccurrence of Severe (Grade 4) Neutropenia in Part 1

Severe (Grade 4) neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of Severe (Grade 4) Neutropenia in Part 1
ParticipantsPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Occurrence of Severe (Grade 4) Neutropenia in Part 140
SecondaryOccurrence of Febrile Neutropenia in Part 1

Each febrile neutropenia event (as defined by Common Terminology Criteria for Adverse Events \[CTCAE\]) was captured as an AE. The occurrence of febrile neutropenia was defined as at least 1 febrile neutropenia event during the treatment period. For the treatment period, the total number of febrile neutropenia events was the number of febrile neutropenia events with a unique start date.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of Febrile Neutropenia in Part 1
ParticipantsPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Occurrence of Febrile Neutropenia in Part 100
SecondaryDuration of Grade 3/4 Neutropenia in Part 1

Grade 3/4 neutropenia was defined as at least 1 ANC value \<1.0 × 10\^9/L during the treatment period. Within each cycle, duration (days) of Grade 3/4 neutropenia was defined as the number of days from the date of the first ANC value of \<1.0 × 10\^9/L observed between start of cycle and end of cycle to the date of the first ANC value ≥1.0 × 10\^9/L that met the following criteria: 1) occurred after the ANC value of \<1.0 × 10\^9/L and 2) no other ANC values \<1.0 × 10\^9/L occurred between this day and end of cycle. The duration of Grade 3/4 neutropenia only included participants who had at least 1 Grade 3/4 neutropenia event in the cycle, and censoring rules were applied for unresolved Grade 3/4 neutropenia in a cycle. For the treatment period, the overall duration of Grade 3/4 neutropenia was the median value among the durations of Grade 3/4 neutropenia from all cycles.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Median · Days
Duration of Grade 3/4 Neutropenia in Part 1
DaysPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Duration of Grade 3/4 Neutropenia in Part 18 (6 to 10)8 (5 to 9)
SecondaryOccurrence of Grade 3/4 Neutropenia in Part 1

Grade 3/4 neutropenia was defined as at least 1 ANC value \<1.0 × 10\^9/L during the treatment period.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of Grade 3/4 Neutropenia in Part 1
ParticipantsPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Occurrence of Grade 3/4 Neutropenia in Part 163
SecondaryNadir of Absolute Neutrophil Count in Cycle 1, Part 1

Cycle nadir was the lowest value for ANC that occurred between start of cycle and end of cycle and was less than the cycle baseline.

Time frame:
From baseline to the end of Cycle 1
Reported as:
Mean · x 10^9 cells/L
Nadir of Absolute Neutrophil Count in Cycle 1, Part 1
x 10^9 cells/LPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Nadir of Absolute Neutrophil Count in Cycle 1, Part 11.198 ± 0.72411.653 ± 0.7381
SecondaryOccurrence of Granulocyte-Colony Stimulating Factor (G-CSF) Administration in Part 1

Administration of G-CSF was collected with concomitant medications, which were coded using World Health Organization Drug Dictionary (WHO-DD) Version September 2017. A cycle where G-CSF was administered concurrently was identified by comparing the start and stop dates of each administration of G-CSF to the start of cycle and end of cycle. The occurrence of G-CSF administrations was defined as at least 1 cycle with G-CSF administrations during the treatment period. For the treatment period, the total number of G-CSF administrations was the number of cycles with G-CSF administrations.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of Granulocyte-Colony Stimulating Factor (G-CSF) Administration in Part 1
ParticipantsPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Occurrence of Granulocyte-Colony Stimulating Factor (G-CSF) Administration in Part 153
SecondaryOccurrence of Red Blood Cell (RBC) Transfusion in Part 1

Within a cycle, a RBC transfusion event was defined as either 1) an actual RBC transfusion, or 2) eligible for RBC transfusion (defined as hemoglobin \<8.0 g/dL). The occurrence of RBC transfusions was defined as at least 1 cycle with RBC transfusion during the treatment period. For the treatment period, the total number of RBC transfusions was the number of cycles with RBC transfusions.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of Red Blood Cell (RBC) Transfusion in Part 1
ParticipantsPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Occurrence of Red Blood Cell (RBC) Transfusion in Part 141
SecondaryChange From Baseline of Hemoglobin at the End of Cycle 6, Part 1

Blood samples were collected for local clinical laboratory assessment of hemoglobin levels.

Time frame:
Baseline, Day 1, Day 3, Day 8, Day 10, and Day 15 of a 21-day cycle x 6
Reported as:
Mean · g/L
Change From Baseline of Hemoglobin at the End of Cycle 6, Part 1
g/LPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Change From Baseline of Hemoglobin at the End of Cycle 6, Part 1-9.8 ± 13.27-20.1 ± 15.21
SecondaryOccurrence of Erythropoietin Stimulating Agent (ESA) Administration in Part 1

Administration of ESAs was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where an ESA was administered concurrently was identified by comparing the start and stop dates of each administration of an ESA to the start of cycle and end of cycle. The occurrence of ESA administration was at least 1 cycle with an ESA administration during the treatment period. For the treatment period, the total number of ESA administrations was the number of cycles with ESA administrations.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of Erythropoietin Stimulating Agent (ESA) Administration in Part 1
ParticipantsPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Occurrence of Erythropoietin Stimulating Agent (ESA) Administration in Part 120
SecondaryOccurrence of Platelet Transfusion in Part 1

Within a cycle, a platelet transfusion event was defined as either 1) an actual platelet transfusion, or 2) eligible for platelet transfusion (defined as a platelet count ≤10 × 10\^9/L). The occurrence of platelet transfusions was defined as at least 1 cycle with platelet transfusion during the treatment period. For the treatment period, the total number of platelet transfusions was the number of cycles with platelet transfusions.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of Platelet Transfusion in Part 1
ParticipantsPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Occurrence of Platelet Transfusion in Part 110
SecondaryChange From Baseline of Platelet Count at the End of Cycle 6, Part 1

Blood samples were collected for local clinical laboratory assessment of platelet count.

Time frame:
Baseline, Day 1, Day 3, Day 8, Day 10, and Day 15 of a 21-day cycle x 6
Reported as:
Mean · x 10^9 cells/L
Change From Baseline of Platelet Count at the End of Cycle 6, Part 1
x 10^9 cells/LPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Change From Baseline of Platelet Count at the End of Cycle 6, Part 1-72.6 ± 88.38-59.4 ± 108.47
SecondaryChange From Baseline of Lymphocyte Count at the End of Cycle 6, Part 1

Blood samples were collected for local clinical laboratory assessment of lymphocyte count.

Time frame:
Baseline, Day 1, Day 3, Day 8, Day 10, and Day 15 of a 21-day cycle x 6
Reported as:
Mean · x 10^9 cells/L
Change From Baseline of Lymphocyte Count at the End of Cycle 6, Part 1
x 10^9 cells/LPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Change From Baseline of Lymphocyte Count at the End of Cycle 6, Part 10.188 ± 0.84310.067 ± 0.4691
SecondaryOccurrence of Dose Reduction in Part 1

Dose reductions were not permitted for trilaciclib, per study protocol. Dose reductions for E/P were derived from changes in the protocol-specified dose on the dosing page and corresponded to the reductions for toxicity specified in the protocol. No more than 2 dose reductions of E/P in total were allowed for any participant. Simultaneous reductions in the doses of E/P were counted as 1 dose reduction. For the treatment period, the total number of dose reductions was the number of cycles where there was at least 1 dose reduction.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of Dose Reduction in Part 1
ParticipantsPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Occurrence of Dose Reduction in Part 123
SecondaryOccurrence of Infectious SAEs in Part 1

SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. An infectious SAE was a serious event in the Medical Dictionary for Regulatory Activities (MedDRA) system organ class "infections and infestations" and a preferred term of anal abscess, bacteraemia, bronchitis, candida infection, chronic sinusitis, conjunctivitis, infection, influenza, nasopharyngitis, oral candidiasis, oral herpes, pharyngitis streptococcal, pneumonia, pneumonia bacterial, respiratory tract infection, sepsis, skin infection, upper respiratory tract infection, urinary tract infection, urosepsis or viral upper respiratory tract infection.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of Infectious SAEs in Part 1
ParticipantsPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Occurrence of Infectious SAEs in Part 121
SecondaryOccurrence of Pulmonary Infection SAE in Part 1

SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. A pulmonary infection SAE was a serious event in the MedDRA system organ class "infections and infestations" and a preferred term of bronchitis, influenza, pneumonia, pneumonia bacterial, respiratory tract infection, upper respiratory tract infection or viral upper respiratory tract infection.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of Pulmonary Infection SAE in Part 1
ParticipantsPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Occurrence of Pulmonary Infection SAE in Part 110
SecondaryOccurrence of IV Antibiotic Administration in Part 1

Intravenous antibiotic administration was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where IV antibiotic was administered concurrently was identified by comparing the start and stop dates of each administration of IV antibiotic to the start of cycle and end of cycle. The occurrence of IV antibiotic administration was defined as at least 1 cycle with IV antibiotic administration during the treatment period. For the treatment period, the total number of IV antibiotic administrations was the number of cycles with IV antibiotic administrations.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of IV Antibiotic Administration in Part 1
ParticipantsPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Occurrence of IV Antibiotic Administration in Part 141
SecondaryTime to First Major Adverse Hematologic Event (MAHE) in Part 1

MAHE was a composite endpoint incorporating the measurement of several clinically meaningful aspects of myelopreservation into a single endpoint. The individual components for MAHE were hospitalization for a hematologic event, febrile neutropenia, death related to treatment, dose delay/reduction due to ANC or platelet counts, prolonged severe neutropenia (duration \>5 days), RBC transfusion (actual or eligible) and platelet transfusion (actual or eligible). Time to first occurrence of a MAHE event was defined as the first time to observe an interested event among all the components, starting from the first dose date of study drug administration.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Median · Months
Time to First Major Adverse Hematologic Event (MAHE) in Part 1
MonthsPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Time to First Major Adverse Hematologic Event (MAHE) in Part 12.6 (0.8 to NA)3.0 (1.0 to NA)
SecondaryBest Overall Tumor Response Based on Assessments in Part 1

Tumor response was assessed by computed tomography (CT) or magnetic resonance imaging (MRI). Overall visit response by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was derived programmatically using data from target lesions (TLs), non-target lesions (NTLs), \& new lesions. Tumor response data were used to determine each participant's time point response \& best overall response (BOR). Complete response (CR) was disappearance of all TLs, any pathological lymph nodes selected as TLs must have reduced in short axis to \<10 mm. Partial response (PR) was at least a 30% decrease from baseline in the sum of diameters of TLs, as long as criteria for progressive disease (PD) were not met. PD was a ≥20% increase in the smallest sum of diameters of TLs since treatment started (including baseline) and an absolute increase of ≥5 mm. Stable disease (SD) was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
Baseline, end of every two 21-day cycles, up until disease progression to a maximum of the time at least 70% overall survival (OS) events observed (a maximum of 4 years)
Reported as:
Count of participants · Participants
Best Overall Tumor Response Based on Assessments in Part 1
ParticipantsPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
CR01
PR87
SD00
PD10
Not evaluable00
Unconfirmed CR10
Unconfirmed PR00
SecondaryBest Overall Tumor Response Based on Blinded Independent Central Review (BICR) Assessments in Part 1

Tumor response was assessed by CT or MRI. Overall visit response by RECIST v1.1 was determined by BICR. Tumor response data were used to determine each participant's time point response \& BOR. CR was disappearance of all TLs, any pathological lymph nodes selected as TLs must have reduced in short axis to \<10 mm. PR was at least a 30% decrease from baseline in the sum of diameters of TLs, as long as criteria for PD were not met. PD was a ≥20% increase in the smallest sum of diameters of TLs since treatment started (including baseline) and an absolute increase of ≥5 mm. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
Baseline, end of every two 21-day cycles, up until disease progression to a maximum of the time at least 70% OS events observed (a maximum of 4 years)
Reported as:
Count of participants · Participants
Best Overall Tumor Response Based on Blinded Independent Central Review (BICR) Assessments in Part 1
ParticipantsPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
CR10
PR68
SD20
PD00
Not evaluable00
Unconfirmed CR00
Unconfirmed PR20
SecondaryProgression Free Survival (PFS) Based on Assessments in Part 1

Tumor response was assessed by CT or MRI. PFS was defined as the time (months) from date of first dose date of study drug for participants in Part 1 until date of documented disease progression or death due to any cause, whichever occurred first. More specifically, PFS was determined using all the assessment data up until the last evaluable visit prior to or on the date of i) disease progression as defined by RECIST 1.1 or by clinical criteria as determined by the investigator; or ii) withdrawal of consent; or iii) receiving subsequent anticancer therapy, whichever was earlier. For PFS determined using response data derived programmatically, either clinical progression or progression by RECIST (whichever came first) was considered. Median and inter-quartile range of PFS were calculated using the Kaplan-Meier method.

Time frame:
Baseline, end of every two 21-day cycles, up until disease progression to a maximum of the time at least 70% OS events observed (a maximum of 4 years)
Reported as:
Median · Months
Progression Free Survival (PFS) Based on Assessments in Part 1
MonthsPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
Progression Free Survival (PFS) Based on Assessments in Part 15.3 (1.5 to 6.1)6.3 (5.9 to 9.1)
SecondaryOS in Part 1

OS was calculated as the time (months) from date of first dose of study drug for participants in Part 1 to the date of death due to any cause. Participants who did not die during the study were censored at the date last known to be alive. Participants lacking data beyond the day of first dose of study drug had their survival time censored at day of first dose of study drug. OS was not censored if a participant received other anti-tumor treatments after the study drugs. Median and inter-quartile range of OS were calculated using the Kaplan-Meier method.

Time frame:
Baseline up until death or a maximum of the time at least 70% OS events observed (a maximum of 4 years)
Reported as:
Median · Months
OS in Part 1
MonthsPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2
OS in Part 110.6 (4.9 to 25.1)12.8 (9.5 to 13.5)
SecondaryOccurrence of Severe (Grade 4) Neutropenia in Part 2

Severe (Grade 4) neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of Severe (Grade 4) Neutropenia in Part 2
ParticipantsPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Occurrence of Severe (Grade 4) Neutropenia in Part 2162
SecondaryOccurrence of Febrile Neutropenia in Part 2

Each febrile neutropenia event (as defined by CTCAE) was captured as an AE. The occurrence of febrile neutropenia was defined as at least 1 febrile neutropenia event during the treatment period. For the treatment period, the total number of febrile neutropenia events was the number of febrile neutropenia events with a unique start date.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of Febrile Neutropenia in Part 2
ParticipantsPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Occurrence of Febrile Neutropenia in Part 231
SecondaryDuration of Grade 3/4 Neutropenia in Part 2

Grade 3/4 neutropenia was defined as at least 1 ANC value \<1.0 × 10\^9/L during the treatment period. Within each cycle, duration (days) of Grade 3/4 neutropenia was defined as the number of days from the date of the first ANC value of \<1.0 × 10\^9/L observed between start of cycle and end of cycle to the date of the first ANC value ≥1.0 × 10\^9/L that met the following criteria: 1) occurred after the ANC value of \<1.0 × 10\^9/L and 2) no other ANC values \<1.0 × 10\^9/L occurred between this day and end of cycle. The duration of Grade 3/4 neutropenia only included participants who had at least 1 Grade 3/4 neutropenia event in the cycle, and censoring rules were applied for unresolved Grade 3/4 neutropenia in a cycle. For the treatment period, the overall duration of Grade 3/4 neutropenia was the median value among the durations of Grade 3/4 neutropenia from all cycles.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Median · Days
Duration of Grade 3/4 Neutropenia in Part 2
DaysPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Duration of Grade 3/4 Neutropenia in Part 28 (7 to 13)8 (6 to 8)
SecondaryOccurrence of Grade 3/4 Neutropenia in Part 2

Grade 3/4 neutropenia was defined as at least 1 ANC value \<1.0 × 10\^9/L during the treatment period.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of Grade 3/4 Neutropenia in Part 2
ParticipantsPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Occurrence of Grade 3/4 Neutropenia in Part 23014
SecondaryNadir of Absolute Neutrophil Count in Cycle 1, Part 2

Cycle nadir was the lowest value for ANC that occurred between start of cycle and end of cycle and was less than the cycle baseline.

Time frame:
From baseline to the end of Cycle 1
Reported as:
Mean · x 10^9 cells/L
Nadir of Absolute Neutrophil Count in Cycle 1, Part 2
x 10^9 cells/LPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Nadir of Absolute Neutrophil Count in Cycle 1, Part 20.815 ± 0.63851.899 ± 1.1930
SecondaryOccurrence of G-CSF Administration in Part 2

Administration of G-CSF was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where G-CSF was administered concurrently was identified bycomparing the start and stop dates of each administration of G-CSF to the start of cycle and end of cycle. The occurrence of G-CSF administrations was defined as at least 1 cycle with G-CSF administrations during the treatment period. For the treatment period, the total number of G-CSF administrations was the number of cycles with G-CSF administrations.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of G-CSF Administration in Part 2
ParticipantsPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Occurrence of G-CSF Administration in Part 2244
SecondaryOccurrence of RBC Transfusion in Part 2

Within a cycle, a RBC transfusion event was defined as either 1) an actual RBC transfusion, or 2) eligible for RBC transfusion (defined as hemoglobin \<8.0 g/dL). The occurrence of RBC transfusions was defined as at least 1 cycle with RBC transfusion during the treatment period. For the treatment period, the total number of RBC transfusions was the number of cycles with RBC transfusions. If a participant did not have any RBC transfusions, they were assigned a value of 0.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of RBC Transfusion in Part 2
ParticipantsPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Overall96
On/after Week 592
SecondaryChange From Baseline of Hemoglobin at the End of Cycle 6, Part 2

Blood samples were collected for local clinical laboratory assessment of hemoglobin levels.

Time frame:
Baseline, Day 1, Day 3, Day 8, Day 10, and Day 15 of a 21-day cycle x 6
Reported as:
Mean · g/L
Change From Baseline of Hemoglobin at the End of Cycle 6, Part 2
g/LPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Change From Baseline of Hemoglobin at the End of Cycle 6, Part 2-25.9 ± 14.63-20.6 ± 13.83
SecondaryOccurrence of ESA Administration in Part 2

Administration of ESAs was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where an ESA was administered concurrently was identified by comparing the start and stop dates of each administration of an ESA to the start of cycle and end of cycle. The occurrence of ESA administration was at least 1 cycle with an ESA administration during the treatment period. For the treatment period, the total number of ESA administrations was the number of cycles with ESA administrations.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of ESA Administration in Part 2
ParticipantsPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Occurrence of ESA Administration in Part 221
SecondaryOccurrence of Platelet Transfusion in Part 2

Within a cycle, a platelet transfusion event was defined as either 1) an actual platelet transfusion, or 2) eligible for platelet transfusion (defined as a platelet count ≤10 × 10\^9/L). The occurrence of platelet transfusions was defined as at least 1 cycle with platelet transfusion during the treatment period. For the treatment period, the total number of platelet transfusions was the number of cycles with platelet transfusions.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of Platelet Transfusion in Part 2
ParticipantsPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Occurrence of Platelet Transfusion in Part 202
SecondaryChange From Baseline of Platelet Count at the End of Cycle 6, Part 2

Blood samples were collected for local clinical laboratory assessment of platelet count.

Time frame:
Baseline, Day 1, Day 3, Day 8, Day 10, and Day 15 of a 21-day cycle x 6
Reported as:
Mean · x 10^9 cells/L
Change From Baseline of Platelet Count at the End of Cycle 6, Part 2
x 10^9 cells/LPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Change From Baseline of Platelet Count at the End of Cycle 6, Part 2-32.7 ± 100.20-54.4 ± 95.44
SecondaryChange From Baseline of Lymphocyte Count at the End of Cycle 6, Part 2

Blood samples were collected for local clinical laboratory assessment of lymphocyte count.

Time frame:
Baseline, Day 1, Day 3, Day 8, Day 10, and Day 15 of a 21-day cycle x 6
Reported as:
Mean · x 10^9 cells/L
Change From Baseline of Lymphocyte Count at the End of Cycle 6, Part 2
x 10^9 cells/LPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Change From Baseline of Lymphocyte Count at the End of Cycle 6, Part 2-0.203 ± 0.43820.104 ± 0.6320
SecondaryOccurrence of Dose Reduction in Part 2

Dose reductions were not permitted for trilaciclib, per study protocol. Dose reductions for E/P were derived from changes in the protocol-specified dose on the dosing page and corresponded to the reductions for toxicity specified in the protocol. No more than 2 dose reductions of E/P in total were allowed for any participant. Simultaneous reductions in the doses of E/P were counted as 1 dose reduction. For the treatment period, the total number of dose reductions was the number of cycles where there was at least 1 dose reduction.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of Dose Reduction in Part 2
ParticipantsPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Occurrence of Dose Reduction in Part 2133
SecondaryOccurrence of Infectious SAEs in Part 2

SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. An infectious SAE was a serious event in the MedDRA system organ class "infections and infestations" and a preferred term of anal abscess, bacteraemia, bronchitis, candida infection, chronic sinusitis, conjunctivitis, infection, influenza, nasopharyngitis, oral candidiasis, oral herpes, pharyngitis streptococcal, pneumonia, pneumonia bacterial, respiratory tract infection, sepsis, skin infection, upper respiratory tract infection, urinary tract infection, urosepsis or viral upper respiratory tract infection.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of Infectious SAEs in Part 2
ParticipantsPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Occurrence of Infectious SAEs in Part 224
SecondaryOccurrence of Pulmonary Infection SAE in Part 2

SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. A pulmonary infection SAE was a serious event in the MedDRA system organ class "infections and infestations" and a preferred term of bronchitis, influenza, pneumonia, pneumonia bacterial, respiratory tract infection, upper respiratory tract infection or viral upper respiratory tract infection.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of Pulmonary Infection SAE in Part 2
ParticipantsPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Occurrence of Pulmonary Infection SAE in Part 214
SecondaryOccurrence of IV Antibiotic Administration in Part 2

Intravenous antibiotic administration was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where IV antibiotic was administered concurrently was identified by comparing the start and stop dates of each administration of IV antibiotic to the start of cycle and end of cycle. The occurrence of IV antibiotic administration was defined as at least 1 cycle with IV antibiotic administration during the treatment period. For the treatment period, the total number of IV antibiotic administrations was the number of cycles with IV antibiotic administrations.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Count of participants · Participants
Occurrence of IV Antibiotic Administration in Part 2
ParticipantsPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Occurrence of IV Antibiotic Administration in Part 288
SecondaryTime to First MAHE in Part 2

MAHE was a composite endpoint incorporating the measurement of several clinically meaningful aspects of myelopreservation into a single endpoint. The individual components for MAHE were hospitalization for a hematologic event, febrile neutropenia, death related to treatment, dose delay/reduction due to ANC or platelet counts, prolonged severe neutropenia (duration \>5 days), RBC transfusion (actual or eligible) and platelet transfusion (actual or eligible). Time to first occurrence of a MAHE event was defined as the first time to observe an interested event among all the components, starting from the first dose date of study drug administration.

Time frame:
From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Reported as:
Median · Months
Time to First MAHE in Part 2
MonthsPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Time to First MAHE in Part 21.0 (0.5 to 2.3)NA (3.3 to NA)
SecondaryBest Overall Tumor Response Based on Assessments in Part 2

Tumor response was assessed by CT or MRI. Overall visit response by RECIST v1.1 was derived programmatically using data from TLs, NTLs, \& new lesions. Tumor response data were used to determine each participant's time point response \& BOR. CR was disappearance of all TLs, any pathological lymph nodes selected as TLs must have reduced in short axis to \<10 mm. PR was at least a 30% decrease from baseline in the sum of diameters of TLs, as long as criteria for PD were not met. PD was a ≥20% increase in the smallest sum of diameters of TLs since treatment started (including baseline) and an absolute increase of ≥5 mm. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
Baseline, end of every two 21-day cycles, up until disease progression to a maximum of the time at least 70% OS events observed (a maximum of 4 years)
Reported as:
Count of participants · Participants
Best Overall Tumor Response Based on Assessments in Part 2
ParticipantsPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
CR10
PR1924
SD129
PD41
Not evaluable10
Unconfirmed CR00
Unconfirmed PR64
SecondaryBest Overall Tumor Response Based on BICR Assessments in Part 2

Tumor response was assessed by CT or MRI. Overall visit response by RECIST v1.1 was determined by BICR. Tumor response data were used to determine each participant's time point response \& BOR. CR was disappearance of all TLs, any pathological lymph nodes selected as TLs must have reduced in short axis to \<10 mm. PR was at least a 30% decrease from baseline in the sum of diameters of TLs, as long as criteria for PD were not met. PD was a ≥20% increase in the smallest sum of diameters of TLs since treatment started (including baseline) and an absolute increase of ≥5 mm. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
Baseline, end of every two 21-day cycles, up until disease progression to a maximum of the time at least 70% OS events observed (a maximum of 4 years)
Reported as:
Count of participants · Participants
Best Overall Tumor Response Based on BICR Assessments in Part 2
ParticipantsPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
CR01
PR2323
SD107
PD42
Not evaluable01
Unconfirmed CR00
Unconfirmed PR54
SecondaryPFS Based on Assessments in Part 2

Tumor response was assessed by CT or MRI. PFS was defined as the time (months) from date of first dose date of study drug for participants in Part 1 until date of documented disease progression or death due to any cause, whichever occurred first. More specifically, PFS was determined using all the assessment data up until the last evaluable visit prior to or on the date of i) disease progression as defined by RECIST 1.1 or by clinical criteria as determined by the investigator; or ii) withdrawal of consent; or iii) receiving subsequent anticancer therapy, whichever was earlier. For PFS determined using response data derived programmatically, either clinical progression or progression by RECIST (whichever came first) was considered. Median and inter-quartile range of PFS were calculated using the Kaplan-Meier method.

Time frame:
Baseline, end of every two 21-day cycles, up until disease progression to a maximum of the time at least 70% OS events observed (a maximum of 4 years)
Reported as:
Median · Months
PFS Based on Assessments in Part 2
MonthsPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
PFS Based on Assessments in Part 25.0 (3.2 to 6.8)6.1 (4.2 to 9.5)
SecondaryOS in Part 2

OS was calculated as the time (months) from date of first dose of study drug for participants in Part 2 to the date of death due to any cause. Participants who did not die during the study were censored at the date last known to be alive. Participants lacking data beyond the day of first dose of study drug had their survival time censored at day of first dose of study drug. OS was not censored if a participant received other anti-tumor treatments after the study drugs. Median and inter-quartile range of OS were calculated using the Kaplan-Meier method.

Time frame:
Baseline up until death or a maximum of the time at least 70% OS events observed (a maximum of 4 years)
Reported as:
Median · Months
OS in Part 2
MonthsPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
OS in Part 210.6 (6.9 to 16.9)10.9 (7.3 to 20.1)
Post-hocDuration of Severe (Grade 4) Neutropenia in Cycle 1 of Part 2

In addition to deriving severe (Grade 4) neutropenia using the method described for the primary endpoints, an approach was applied that accounted for participants who did not experience a severe neutropenia event in Cycle 1. For the post-hoc analysis, severe neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period. In Cycle 1, the duration (days) of severe neutropenia was defined as the number of days from the date of the first ANC value of \<0.5 × 10\^9/L observed between start of cycle and end of cycle to the date of the first ANC value ≥0.5 × 10\^9/L that met the following criteria: 1) occurred after the ANC value of \<0.5 × 10\^9/L and 2) no other ANC values \<0.5 × 10\^9/L occurred between this day and end of cycle. The duration of severe neutropenia was set to 0 for participants who did not experience severe neutropenia in Cycle 1. Data from unscheduled visits and the actual assessment date (rather than visit date) were included in the derivation.

Time frame:
From baseline to the end of Cycle 1
Reported as:
Median · Days
Duration of Severe (Grade 4) Neutropenia in Cycle 1 of Part 2
DaysPart 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Duration of Severe (Grade 4) Neutropenia in Cycle 1 of Part 20 (0 to 13)0 (0 to 3)

Adverse events

Collected over All AEs occurring from the first date of administration of trilaciclib or placebo + E/P therapy through and including 30 calendar days after the last administration of trilaciclib or placebo + E/P therapy were recorded (a minimum of 51 days up to a maximum of 374 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Cohort 1 Trilaciclib 200 mg/m^29/12 (75%)4/12 (33.3%)12/12 (100%)
Part 1: Cohort 2 Trilaciclib 240mg/m^28/8 (100%)1/8 (12.5%)8/8 (100%)
Part 2: Placebo28/37 (75.7%)9/37 (24.3%)36/37 (97.3%)
Part 2: Trilaciclib 240 mg/m^228/38 (73.7%)11/38 (28.9%)37/38 (97.4%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2Part 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
Cardiac failure chronicCardiac disorders0/121/80/370/38
StomatitisGastrointestinal disorders0/121/80/370/38
Oral candidiasisInfections and infestations0/121/80/370/38
Myocardial infarctionCardiac disorders1/120/80/370/38
Bone painMusculoskeletal and connective tissue disorders1/120/80/370/38
PneumoniaInfections and infestations1/120/81/372/38
UrosepsisInfections and infestations1/120/80/370/38
AnemiaBlood and lymphatic system disorders0/120/82/370/38
Respiratory failureRespiratory, thoracic and mediastinal disorders0/120/81/372/38
Deep vein thrombosisVascular disorders0/120/81/370/38
Most frequent other events
Showing 10 of 45
Most frequent other events
EventPart 1: Cohort 1 Trilaciclib 200 mg/m^2Part 1: Cohort 2 Trilaciclib 240mg/m^2Part 2: PlaceboPart 2: Trilaciclib 240 mg/m^2
NeutropeniaBlood and lymphatic system disorders5/125/823/379/38
FatigueGeneral disorders7/124/86/3716/38
NauseaGastrointestinal disorders5/124/88/3713/38
ConstipationGastrointestinal disorders4/124/88/379/38
VomitingGastrointestinal disorders4/124/85/373/38
ArthralgiaMusculoskeletal and connective tissue disorders2/124/83/375/38
DehydrationMetabolism and nutrition disorders1/124/81/370/38
AnemiaBlood and lymphatic system disorders5/121/815/3710/38
LeukopeniaBlood and lymphatic system disorders5/120/85/372/38
AlopeciaSkin and subcutaneous tissue disorders5/123/811/376/38

Baseline characteristics

All participants randomized

Age, Categorical
Age, Categorical(Participants)Part 1: Dose Finding/ExpansionPart 2: Trilaciclib/Placebo IV With E/PTotal
<=18 years000
Between 18 and 65 years73744
>=65 years124052
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Dose Finding/ExpansionPart 2: Trilaciclib/Placebo IV With E/PTotal
Female82331
Male115465
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Dose Finding/ExpansionPart 2: Trilaciclib/Placebo IV With E/PTotal
Hispanic or Latino123
Not Hispanic or Latino187593
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Dose Finding/ExpansionPart 2: Trilaciclib/Placebo IV With E/PTotal
American Indian or Alaska Native011
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American314
White167389
More than one race000
Unknown or Not Reported011
Country
Country(Participants)Part 1: Dose Finding/ExpansionPart 2: Trilaciclib/Placebo IV With E/PTotal
United States193958
Non-United States03838
Body Surface Area
Body Surface Area(m^2)Part 1: Dose Finding/ExpansionPart 2: Trilaciclib/Placebo IV With E/PTotal
Mean1.90 ± 0.2631.90 ± 0.216NA ± NA
08

Study locations

40 sites
  • Genesis Cancer Center
    Hot Springs, Arkansas 71913, United States
  • Highlands Oncology Group
    Rogers, Arkansas 72758, United States
  • The Oncology Institute of Hope and Innovation
    Whittier, California 90603, United States
  • Memorial Hospital - Univ. of Colorado Health
    Colorado Springs, Colorado 80909, United States
  • University of Colorado Health, Oncology Clinical Research Northern Region
    Fort Collins, Colorado 80528, United States
  • Boca Raton Regional Hospital - Lynn Cancer Institute
    Boca Raton, Florida 33486, United States
  • Florida Cancer Specialists - South
    Fort Myers, Florida 33916, United States
  • Florida Cancer Specialists - North
    Tavares, Florida 32778, United States
  • Florida Cancer Specialists - East
    West Palm Beach, Florida 33401, United States
  • University Cancer and Blood Center, LLC
    Athens, Georgia 30607, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40202, United States
  • Center For Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Norris Cotton Cancer Center
    Lebanon, New Hampshire 03756, United States
  • University of New Mexico Comprehensive Cancer Center
    Albuquerque, New Mexico 87106, United States
  • Roswell Park
    Buffalo, New York 14263, United States
  • UNC - Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina 27514, United States
  • Oklahoma University - Peggy and Charles Stephenson Cancer Center
    Oklahoma City, Oklahoma 73117, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Guthrie Medical Group, PC
    Sayre, Pennsylvania 18840, United States
  • Greenville Health System
    Greenville, South Carolina 29605, United States
  • Gibbs Cancer Center
    Spartanburg, South Carolina 29203, United States
  • Tennessee Cancer Specialists
    Knoxville, Tennessee 37909, United States
  • Hanna Cancer Associates - University of Tennessee
    Knoxville, Tennessee 37920, United States
  • Texas Oncology
    Tyler, Texas 75702, United States
  • Northwest Cancer Specialists, P.C.
    Vancouver, Washington 98684, United States
  • CHU de Rennes Hopital Pontchaillou
    Rennes, 35033, France
  • ARENSIA Exploratory Medicine LLC
    Tbilisi, 0112, Georgia
  • Veszprem Megyei Tudogyogyintezet
    Farkasgyepu, Veszprem 8582, Hungary
  • Orszagos Koranyi Tbc es Pulmonologiai Intezet, XI. Tudobelosztaly
    Budapest, 1121, Hungary
  • Hetenyi Geza Korhaz
    Szolnok, 5000, Hungary
  • ARENSIA Exploratory Medicine Phase I Unit, The Institute of Oncology
    Chisinau, 2025, Moldova, Republic of
  • Samodzielny Publiczny ZespAA GruAicy i ChorAb PA¿uc
    Olsztyn, 10-357, Poland
  • Wojewodzki Szpital Zespolony im. L. Rydygiera
    Torun, 87-100, Poland
  • Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie
    Warszawa, 02-781, Poland
  • Hospital Regional Universitario HRU Carlos Haya Malaga
    Malaga, Andalucia 29010, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Consorcio Hospitalario Provincial
    Castillón, 12002, Spain
  • Hgu Gregorio Maranon
    Madrid, 28009, Spain
  • Fundacion Jimenez Diaz
    Madrid, 28040, Spain
09

References and documents

Publications

  • Hussein M, Maglakelidze M, Richards DA, Sabatini M, Gersten TA, Lerro K, Sinielnikov I, Spira A, Pritchett Y, Antal JM, Malik R, Beck JT. Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies. Cancer Manag Res. 2021 Aug 9;13:6207-6218. doi: 10.2147/CMAR.S313045. eCollection 2021. PubMed 34408488 ↗
  • Ferrarotto R, Anderson I, Medgyasszay B, Garcia-Campelo MR, Edenfield W, Feinstein TM, Johnson JM, Kalmadi S, Lammers PE, Sanchez-Hernandez A, Pritchett Y, Morris SR, Malik RK, Csoszi T. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials. Cancer Med. 2021 Sep;10(17):5748-5756. doi: 10.1002/cam4.4089. Epub 2021 Aug 18. PubMed 34405547 ↗
  • Li C, Hart L, Owonikoko TK, Aljumaily R, Rocha Lima CM, Conkling PR, Webb RT, Jotte RM, Schuster S, Edenfield WJ, Smith DA, Sale M, Roberts PJ, Malik RK, Sorrentino JA. Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer. Cancer Chemother Pharmacol. 2021 May;87(5):689-700. doi: 10.1007/s00280-021-04239-9. Epub 2021 Feb 17. PubMed 33595690 ↗
  • Lai AY, Sorrentino JA, Dragnev KH, Weiss JM, Owonikoko TK, Rytlewski JA, Hood J, Yang Z, Malik RK, Strum JC, Roberts PJ. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. J Immunother Cancer. 2020 Oct;8(2):e000847. doi: 10.1136/jitc-2020-000847. PubMed 33004541 ↗
  • Weiss JM, Csoszi T, Maglakelidze M, Hoyer RJ, Beck JT, Domine Gomez M, Lowczak A, Aljumaily R, Rocha Lima CM, Boccia RV, Hanna W, Nikolinakos P, Chiu VK, Owonikoko TK, Schuster SR, Hussein MA, Richards DA, Sawrycki P, Bulat I, Hamm JT, Hart LL, Adler S, Antal JM, Lai AY, Sorrentino JA, Yang Z, Malik RK, Morris SR, Roberts PJ, Dragnev KH; G1T28-02 Study Group. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019 Oct 1;30(10):1613-1621. doi: 10.1093/annonc/mdz278. PubMed 31504118 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Jul 2017, 24 months.

Results were first posted in Jul 2020, 3 years after primary completion. A results delay was requested in Nov 2018.

Of 71 industry-sponsored phase 1/2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 74. This study's 24 months is below that.

Counting every sponsor, half of 98 studies reached it within 54 months; a quarter within 44 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2015
First posted
Jul 16, 2015
StartActual
Jun 26, 2015
Primary completionActual
Jul 3, 2017
CompletionActual
Feb 22, 2019
Results delay requested
Nov 14, 2018
Results first posted
Jul 9, 2020
Last update
Aug 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02499770
Responsible party
Sponsor
First posted
Jul 16, 2015
Start date
Jun 26, 2015
Primary completion
Jul 3, 2017
Completion
Feb 22, 2019
Results posted
Jul 9, 2020
Last update
Aug 21, 2020

Study contacts

Clinical Contact
study director · G1 Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trilaciclib

Start the discussion